The Texas Commission on Environmental Quality (TCEQ) developed guidance on conducting systematic reviews during the development of chemical-specific toxicity factors. Using elements from publicly available frameworks, the TCEQ systematic review process was developed in order to supplement the existing TCEQ Guidelines for developing toxicity factors (TCEQ Regulatory Guidance 442). The TCEQ systematic review process includes six steps: 1) Problem Formulation; 2) Systematic Literature Review and Study Selection; 3) Data Extraction; 4) Study Quality and Risk of Bias Assessment; 5) Evidence Integration and Endpoint Determination; and 6) Confidence Rating. This document provides guidance on conducting a systematic literature review and integrating evidence from different data streams when developing chemical-specific reference values (ReVs) and unit risk factors (URFs). However, this process can also be modified or expanded to address other questions that would benefit from systematic review practices. The systematic review and evidence integration framework can improve regulatory decisionmaking processes, increase transparency, minimize bias, improve consistency between different risk assessments, and further improve confidence in toxicity factor development.
Introduction
A systematic review is defined as a high-level review of the available, relevant information in order to extract and analyze all data to address a specific research question. Systematic reviews are becoming an integral part of risk assessments since key steps of the process include using explicit, reproducible methods to identify, select and critically evaluate all quality research in order to minimize bias and provide reliable findings (Cochrane Collaboration, 2011) . The use of explicit study inclusion/exclusion criteria is critical in increasing transparency of why particular studies are chosen as potential key studies while others are omitted. Since data are collected from diverse evidence streams (e.g., human clinical data, epidemiological data, animal toxicological studies, mechanistic data), there is a need to evaluate and integrate information from multiple data streams to improve the decision-making process, increase transparency, minimize bias, and improve consistency between different risk assessments.
Several recent publications have proposed best practices for conducting systematic reviews for chemical toxicity assessments (Rhomberg et al., 2013; NRC, 2014; Rooney et al., 2014) . For example, the Office of Health Assessment and Translation (OHAT) Division of the National Toxicology Program (NTP), in the National Institute of Environmental Health Services (NIEHS), recently published their method for conducting systematic reviews and evidence integration for reaching hazard identification conclusions (Rooney et al., 2014) . The overall objective of this guidance is to provide information on conducting a systematic review in concurrence with the development of chemical-specific toxicity factors based on evidence from human, animal, and mechanistic studies. Fig. 1 depicts the TCEQ systematic review and evidence integration process. In general, derivation of chemical reference values (ReVs) or unit risk factors (URFs) begins with a toxicity assessment involving hazard identification, dose-response assessment, and the evaluation of a chemical's mode of action. The toxicity factors developed by the TCEQ are derived to protect potentially sensitive populations, such as children, pregnant women and the elderly; thus, all available health endpoints and various types of studies are considered in order to determine the most sensitive health endpoint (i.e., critical effect) in the most [relevant or] sensitive species. This guidance, in principle, must also be applicable for chemicals for which limited toxicity data are available. Therefore, the TCEQ used the available existing methodologies to develop guidelines for conducting systematic reviews and integrating evidence when developing chemical-specific reference values (ReVs) and unit risk factors (URFs).
Systematic review and evidence integration framework

Problem formulation
The first step in the systematic review and evidence integration process is problem formulation (Fig. 1 ). This step identifies and specifically states the research question and describes the extent of the evaluation. Problem formulation contains elements that promote transparency and consistency, and can accommodate different biologically plausible hypotheses (Rhomberg et al., 2013) .
For the derivation of toxicity factors, the TCEQ reviews all available data to identify the critical effect that occurs at the lowest human equivalent concentration or dose. The TCEQ's Guidelines to Develop Toxicity Factors (TCEQ, 2015) is a peer-reviewed publication that outlines the process of critically evaluating a variety of health outcomes and focusing resources on human-relevant adverse health endpoints. The process begins with the selection of a chemical, followed by the review of the physical and chemical properties and a critical review of dose-response data for all of the available health endpoints. The empirical evidence is examined thoroughly to determine the no observed adverse effect level (NOAEL) and/or the lowest observed adverse effect level (LOAEL) . When data are available, Benchmark Dose Software (BMDS) is used to develop dose-response curves and to establish a point of departure (POD) . To the extent possible, determination of the most appropriate mode of action (MOA) for the most sensitive (i.e., critical) adverse endpoint is also included in the analysis. An MOA analysis is important in understanding the potential for toxicity and the most scientifically-defensible extrapolation to lower exposures (USEPA, 2005) . Assessing the confidence in the hypothesized or previously propounded MOAs for a critical effect is addressed and described in more detail in Becker et al. (2017) .
The problem formulation should be articulated clearly to prevent the systematic review and evidence integration process from becoming unduly resource intensive and to ensure that chemical specific toxicity values are protective of human health and welfare. The output of the problem formulation step is a statement that includes specific questions pertinent to all of the steps of the systematic review process, including the literature search, study selection, data extraction, and synthesis. Examples of specific questions to structure the problem formulation are included below:
What is the chemical for which the toxicity factor is being developed? What are the physical and chemical properties of the chemical? What is/are the critical effect(s)? Are there potentially sensitive subpopulations? What is the MOA? (described in detail in Becker et al., 2017) Protocol development is another important aspect in the initial step of the systematic review process. A protocol is typically developed around a PECO (Populations, Exposure, Control, and Outcomes) statement (Rooney et al., 2014) . These identifiers are used to lay out the framework for the literature search and inclusion/exclusion criteria. The PECO statement is particularly helpful if specific aspects of the review have already been identified prior to the literature search, such as species of interest, critical health endpoint, route-of-exposure, or MOA. For example, most chemical assessments conducted by the TCEQ meet criteria in Table 1 .
In the TCEQ framework, the problem formulation and the protocol are written in a general manner because they must be applicable to a wide array of chemicals, data sets, and endpoints. For the purpose of conducting systematic reviews and integrating evidence for determining toxicity factors, the TCEQ uses the following protocol as a guideline. Detailed descriptions of the protocol used by the TCEQ to develop toxicity factors can be found in TCEQ (2015) and the steps to the overall protocol are summarized here. The general objective of the literature search strategy for a specific chemical risk assessment is to identify all relevant studies, which may include both published and unpublished studies. The TCEQ conducts thorough literature searches of relevant databases and takes other prudent steps to identify relevant studies during the literature review. For example, several months prior to the start of work on a toxicity factor, the TCEQ conducts a scoping exercise to identify all available toxicity information for the chemical. The TCEQ announces this process using its email listserve to solicit information for a particular chemical or class of chemicals; interested parties are encouraged to provide citations or toxicological information. Chapter 1 of the TCEQ (2015) Guidelines provides more detailed information on the selection of chemicals and data solicitation.
Selecting databases and sources
Initially, publically available databases (Table 2) are searched using explicitly stated search criteria. Additionally, several governmental and private sector organizations can be consulted for previously published scientific literature and toxicity values for chemicals. This list of available databases is dynamic, and other sources and databases may be added if deemed necessary or advantageous for the toxicity factor derivation process.
Selecting search terms
Adequate searching of the scientific literature is a vital part of the systematic review process. To the extent possible, search terms should be thoughtfully selected to appropriately narrow down search results for data-rich chemicals that would otherwise produce an exhaustive amount of literature, much of which found to be irrelevant to toxicity factor derivation. An example of how this search criterion can be recorded is provided in Table A .1 in the Appendix.
Maintain a record of searches
Currently, there are several tools available to help inform decisions and transparently document the systematic literature review process. These tools, which can help maintain references in one place and group them based on the selection criteria, can be powerful because they allow query of the identified studies, and improve transparency of the inclusion/exclusion process.
The TCEQ utilizes the HAWC (Health Assessment Workspace Collaboration) software to conduct the literature search, compile references from PubMed and other sources, tag literature for inclusion or exclusion, and analyze the available literature. HAWC is an open source, modular, content management system designed to synthesize multiple data sources into overall human health assessments of chemicals. The system integrates and documents workflow from the literature search to data extraction, synthesis, and interpretation. Human health assessments of chemicals are best documented with a systematic review of the scientific literature, and depending on the chemical may require a large amount of data extraction, synthesis, and interpretation by teams of experts across multiple fields. HAWC creates a workspace for interested parties, including reviewers and stakeholders, to have dynamic access to on-going and completed assessments (HAWC, 2013).
Inclusion and exclusion criteria
One particular strength of the systematic review approach is the documentation of clear study inclusion/exclusion criteria. This step is useful in documenting why certain studies were chosen as potential key studies and the reasons for excluding other studies (i.e., excluding them as potential key studies or completely excluding studies from the review). The inclusion and exclusion criteria are formulated based on the specific questions that are established during the problem formulation step. For example, the criteria are based on adverse health outcomes, exposures, durations, and the types of studies relevant to the toxicity factor being developed. Studies that contribute to identifying the relevant critical effect(s) are selected for further review. Developing explicit criteria a priori to select or omit studies helps to provide clear and transparent documentation that can be easily reproduced by other researchers if needed, which in turn can improve confidence in the TCEQ's derivation of toxicity factors.
Several study-specific questions can be asked to determine whether a study should be included or excluded (examples are included in Table 3 ). Defining one set of inclusion and exclusion criteria for all chemicals is difficult since often the criteria will be chemical and/or purpose-specific. Therefore, inclusion and exclusion criteria may be modified as needed and should be documented appropriately. More stringent exclusion criteria may be required for data-rich chemicals in order to narrow down the pool of available literature to only those studies relevant to the specific assessment being conducted. For a thorough review, two or more individuals should review each piece of literature identified from the scientific literature search and classify the journal articles based on the specific inclusion/exclusion criteria utilized.
Data extraction
Data extraction is the third step in the systematic review process (Fig.1) . During the data extraction step, studies that meet the inclusion criteria are further critically reviewed and adverse health endpoint data are summarized into evidence tables. Table 4 is an example of an evidence table, and Tables A5eA7 in the Appendix are examples of how these tables can be used during the derivation of a specific toxicity factor. The purpose of these tables or databases is to display an overall view of the available data in the literature, identify potential trends in PODs, and to provide a basis to use the data as evidence.
Data extraction will differ for each data stream because of differences in study design, methodologies, and data quality. Epidemiology studies include experimental and observational (analytical and descriptive) studies. Animal toxicity studies are conducted to determine dose-response, and are usually conducted for particular durations (i.e., acute, subacute, subchronic, chronic), or to study a specific effect (e.g., carcinogencity, reproductive/developmental, neurological). Mechanistic or in vitro studies are often conducted to determine genotoxic potential, cell transformation, cytotoxicity, or to understand the MOA, but they are often difficult to extrapolate to human-relevant exposures. Toxicity factors are based on a database of the most reliable information available (see Step 4 below) so that the values reflect the most scientifically-supported information on the potential hazards of the chemical and dose-response.
Assessing the quality of individual studies and risk of bias
Assessing data quality is a critical step in risk assessment and therefore the systematic review process (Fig. 1) . Studies that meet the inclusion criteria should be critically evaluated for study quality and risk of bias (ROB). Studies that were excluded based on previously stated criteria are not assessed for study quality and ROB. Section 3.3.3.1 of the TCEQ (2015) guidance briefly discusses that data quality evaluations should consider method validity, reproducibility, study reliability, dose-response relationships, temporal associations between exposures and adverse health effects, and whether critical effects are relevant to humans. ROB is a concept that was defined by the Institute of Medicine (IOM) as the "extent to which flaws in the design and execution of a collection of studies could bias the estimate of effect for each outcome under the study" (IOM, 2001 as described in NRC, 2014 . According to the National Academy of Sciences (NRC, 2014) , bias is defined as an error that decreases validity, and ROB refers to the potential for bias to occur.
Although study quality and ROB are interrelated to some extent, the NRC review of the United States Environmental Protection Agency's (USEPA) Integrated Risk Information System (IRIS) assessment recommends treating the terms separately. However, the NTP OHAT review defines study quality broadly with three main elements, including ROB: 1) reporting quality, which relates to the way the study was reported; 2) internal validity or ROB, which refers to how plausible the results of the study are and depends on how the study was designed and conducted; and 3) external validity or directness of applicability, which refers to evaluating whether the study is pertinent and applicable for the particular issue being considered (Rooney et al., 2014) . The Rooney et al. (2014) review provided a comprehensive set of questions to address ROB for the different streams of data including experimental animal studies, human chamber studies, and epidemiology studies. The TCEQ uses the Rooney et al. (2014) recommendations for ROB as a guide in the development of study quality criteria. The TCEQ considers the evaluation of study quality and ROB as a single step in the systematic review process in order to efficiently review the included human, animal, and mechanistic studies.
Risk assessments often include information from different streams of data (e.g., animal studies, human inhalation chamber studies, epidemiology studies). Each of these categories is different from the other in study design, study protocol, exposure, and species examined. In addition, toxicology guideline studies are also included, if relevant, in the assessment of study quality and ROB process but do not receive special consideration. While study quality is a critical component of risk assessment, there are no specific guidelines on how to collectively assess the overall study quality for all of the available data from different data streams. Additionally, defining a distinct set of rules across the different types of studies can be difficult. The TCEQ's guidance defines study type score criteria (Tables 5e8) to determine study quality for individual studies when deriving toxicity factors. Each of the selected studies is evaluated for study quality and ROB based on a number of attributes. The attributes are scored on a scale of 1 to À1, with 1 meaning the study possessed the specific attribute, 0 meaning the study did not examine the attribute, and À1 meaning the study lacked the attribute ( Table 5 ). The total scores are then summed as a guide to compare studies within each evidence group; however, because each evidence group has a different number of scoring criteria, totals cannot be compared across the different data streams. Using scientific judgment, studies are then labeled as key, supporting or informative in nature. The general guidelines for scoring criteria provide a means to evaluate all studies, regardless of type, to determine the overall quality of the study.
Human studies
Human studies are preferred over animal studies when developing toxicity factors, as the need to conduct animal-to-human extrapolation (e.g., dose, effect) is unnecessary, and uncertainty is decreased. However, while there is guidance on how to conduct human epidemiology studies, there is limited guidance on evaluating the integrity of the study designs and interpretation of the findings.
Section 3.3.3.3 of the TCEQ (2015) guidance explains that epidemiology studies provide data regarding associations between exposure and health effects that are useful in hazard identification, and if accompanied by sufficient, accurate and reliable exposure data, may be useful in the dose-response assessment for a toxicant. However, epidemiological data often lack exposure information and may have confounding issues and bias. These issues can reduce confidence due to more uncertainty. Among other considerations (e.g., Bradford Hill criteria), strengths, weaknesses, and ROB should be weighed prior to making a causal association based on epidemiology studies. Further, statistically significant results should not be automatically deemed as evidence of a causal association (e.g., adequate controls or adjustments for confounders may not have been made, and chance may be responsible especially when numerous comparisons have been made). Thus, a positive association does not necessarily imply causation (Phillips and Goodman, 2004) . However, if sufficient exposure data are available and the quality is high, epidemiology studies should be used for doseresponse assessment as human studies are preferred over animal studies when developing toxicity factors, since the need to conduct animal-to-human extrapolation (e.g., dose, effect) is unnecessary and uncertainty is decreased.
As mentioned previously, a consensus among the scientific community on how to evaluate and rate different types of epidemiology studies is needed. Money et al. (2013) proposed a systematic review process for evaluating and scoring human data that builds on previously published information, proposed by Klimisch et al. (1997) for animal studies. The authors adapted the reliability scores to human studies to provide a comparable categorization in addressing evidence integration. However, the authors note that the interpretation of human data is not as straightforward as animal data due to variability in study designs, human genetic variation, and the importance of accounting for confounding and bias. Therefore, assigning quality scores to human data is a challenge and professional judgment is a key factor in the process. Table 6 is an example of how the TCEQ incorporates the assessment of study quality for human data. Table 6 is used in conjunction with Table 5 (general criteria) to identify additional study quality and ROB scoring criteria when evaluating human studies. These criteria may be revised as needed to better assess the available data. An example of how these criteria were used in the development of toxicity factors for ethylene glycol can be found in Table A .13 in the Appendix.
Animal studies
Klimisch et al. (1997) proposed a systematic approach for evaluating the quality of experimental toxicological and ecotoxicological data. The authors identified three categories (Reliability, Relevance, and Adequacy) to evaluate data quality in animal studies. However, the authors focused only on the reliability category to determine the Klimisch score (relevance and adequacy were not evaluated). The TCEQ uses a variation of the Klimisch score method to include relevance and adequacy in the final scoring criteria (Table 7) . Klimisch et al. (1997) stated that the more details provided on procedures, methodology and analytics, the more reliable and thorough the evaluation will be. In addition, the (2015) guidance, studies that contribute most significantly to the evidence integration and that identify adverse effects relevant to humans are selected as key studies. For example, inhalation exposure studies usually take precedence over oral exposure studies for deriving inhalation toxicity factors and, conversely, oral exposure studies typically take precedence over inhalation studies for deriving oral toxicity factors. In addition, in the absence of adequate human data, animal studies and adverse effects that are known or likely to be relevant to humans are preferred as key studies. Section 3.3.3.4, Section 3.4, and Figs. 3e1 of the TCEQ (2015) guidance depicts the main steps in evaluating the human relevance of an animal MOA to humans. Section 3.15 of TCEQ (2015) guidance provides considerations for chemicals that are limited in data. Table 7 should be used in conjunction with Table 5 (general criteria) to identify additional study quality and ROB scoring criteria when evaluating animal studies. An example of how these criteria were used in the development of toxicity factors for ethylene glycol can be found in Table A .10 of the Appendix.
Mechanistic studies
Traditional risk assessments that rely primarily on in vivo testing have several limitations. The time and expense needed for in vivo toxicity testing are often prohibitive in terms of testing the vast influx of chemicals in commerce. In vitro testing has gained popularity because in vitro assays, in theory, can generate molecular, biochemical, or histological data and can be easily scaled to high-throughput systems, and therefore can potentially be used to screen a large number of chemicals in a short period of time. A critical challenge to using this type of mechanistic information, however, is translating outcomes to relevant risk assessment and risk management objectives (i.e., protection of individuals or populations) in a toxicologically-predictive manner. Computational systems biology toxicity pathway models must be further developed and validated to reliably distinguish non-adverse responses (or levels of responses) for in vitro endpoints (e.g., adaptive) from those that should be deemed adverse at the cellular level (e.g., produce progressive toxicity pathway perturbations sufficient to cause adverse effects in vivo) (TCEQ, 2015) . When available, the TCEQ will use in vitro e in vivo extrapolation (IVIVE) tools to predict in vivo effects. As stated in the TCEQ (2015) Guidelines, once the POD for each key study is determined, adjustments must be made to account for differences between experimental and desired exposure durations and/or differences in anatomy and physiology in experimental animals and humans. A comprehensive biologically-based doseresponse model links mechanistic determinants of chemical disposition, toxicant-target interactions, and tissue responses into an overall model of pathogenesis. The proposed stages between exposure and response include processes relating exposure to consequent tissue dose (i.e., toxicokinetics) and processes that determine response to the tissue dose (i.e., toxicodynamics). If empirical data are not available to construct a comprehensive biologically-based dose-response model for a chemical, then response can be related to exposure by incorporating and integrating as much mechanistic data as possible to allow for a more accurate characterization of the pathogenic process (TCEQ, 2015) . When possible, the TCEQ uses verified physiologically-based pharmacokinetic (PBPK) compartmental models to characterize pharmacokinetic (a.k.a. toxicokinetic) behavior of a chemical and to perform dosimetric adjustments (TCEQ, 2015) . Table 8 should be used in conjunction with Table 5 (general criteria) to identify additional study quality and ROB scoring criteria when evaluating mechanistic studies. An example of how these criteria were used in the development of toxicity factors for ethylene glycol can be found in Table A .11 in the Appendix.
Evidence integration
Evidence integration is a two-step process. In the first step, evidence from each stream of data (animal studies, human studies, and mechanistic) is identified. In the second step, the evidence from the individual streams is combined with the other streams of data. Since chemicals differ in the amount and quality of each stream of data, prescribing universally applicable rules for evidence integration is difficult. Additionally, the different types of data also have different strengths and weakness. The challenge is to determine objectives a priori so that evidence integration can be conducted in a transparent and consistent manner. Properly conducted evidence integration of all of the available data from the different streams allows confidence in the body of evidence as a whole to be rated when making causal determinations.
The TCEQ provides evidence integration tables to summarize the available data for toxicity factor derivation. These tables explain the reasoning behind designating studies as key, supporting, or informative. Examples of evidence integration tables used during the derivation of the ethylene glycol toxicity factors can be found in Tables A.16eA .18 in the Appendix. Due to the variety of chemicals and toxicity factors that are developed, these tables may be altered by TCEQ as needed.
Rate the confidence in the body of evidence
In this step, the confidence in the whole body of evidence is evaluated. The confidence in the body of evidence is determined by evaluating all of the elements, including type of data, study design, study quality, sample size, human relevance, and ROB that are discussed in detail in the previous steps. For example, good quality studies and lower ROB can translate to higher ratings that, in turn, indicate greater confidence and lower uncertainty that the key study findings accurately depict a true association between exposure and effect. Section 7.13 of the TCEQ (2015) guidance briefly describes the importance of recognizing and characterizing uncertainties. Higher confidence ratings generally coincide with lower uncertainty factors. Appropriately applying uncertainty factors is critical because the evidence integration approach requires some scientific judgment, use of assumptions, and data extrapolations. In addition, toxicity assessments often differ amongst scientists and regulatory agencies, and documenting uncertainties of the final toxicity values provides a transparent approach to illuminating differences in derivations. Beck et al. (2015) developed an assessment tool that deconstructs toxicity development into elements (database completeness, systematic review, key study quality, critical effect, relevance of critical effect, point of departure, human equivalent point of departure, sensitive populations, peer review, and toxicity value comparison), and recommends scoring confidence and uncertainty for each element separately. Evaluating the elements separately allows users of toxicity values to clearly understand the inherent uncertainty of each step of the process. The authors identified major elements for both non-cancer and cancer assessments. Because many of the aspects of the elements are interrelated, the TCEQ combined the evaluations for simplicity. However, adjustments to the assessment may be made on a case-by-case basis. Table 9 provides the name of the element and the magnitude of the confidence in the elements using a qualitative ranking system of low, medium, or high confidence. Table A .20 in the Appendix provides an example of how Table 9 would be used in an actual assessment for displaying the overall confidence in a toxicity assessment (for ethylene glycol) using a single metric/table. The format portrays the relative picture of the overall uncertainty and provides a rapid visualization of the confidence scoring for the overall toxicity assessment (Beck et al., 2015) .
Limitations
The TCEQ recognizes that there are complex limitations in the proposed systematic review approach regarding the development of chemical-specific toxicity factors. In general, we understand that ultimately relying on "expert judgment" is a limitation of systematic reviews. However, the nature of regulatory risk assessment is inherently reliant on sound scientific judgment informed by the body of scientific data. The point of the systematic review process aims to document the scientific basis for those judgments and ultimately improve the decision-making process, increase transparency, minimize bias, and improve consistency between different risk assessments.
Problem Formulation and Protocol Development:
In this framework, the problem formulation and the protocol development sections are presented in a general manner because they must be applicable to a wide array of chemicals, data sets, and endpoints. Due to the regulatory nature of the TCEQ toxicology program, this guidance must also be applicable for chemicals for which limited toxicity data are available. Therefore, the guidelines are designed to be versatile depending on the chemical under assessment. Documenting changes made to the systematic review framework will minimize bias and increase transparency in the scientific basis for regulatory decisions. 2. Literature Searches: The TCEQ conducts thorough literature searches of relevant databases and takes prudent steps to identify all relevant studies during the literature review process. While initial search terms may limit the identification of relevant literature, the review of additional sources (e.g., toxicological reviews) allows for identification of other relevant literature for inclusion and the refinement of search criteria. 3. Inclusion and Exclusion Criteria: Defining one set of inclusion and exclusion criteria for all chemicals is difficult since often the criteria will be chemical and/or purpose-specific. Therefore, inclusion and exclusion criteria may be modified based on scientific judgment as needed to allow for the identification of other relevant literature as long as the changes are documented. 4. Scoring criteria: Defining a distinct set of rules across the different types of studies and data streams can be difficult. These criteria may be revised as needed to better assess the available data depending on the chemical under assessment. In addition, the study quality criteria provided are general and subject to scientific judgement and interpretation. The TCEQ will consider reliability testing in the future to enhance the application of these criteria.
Conclusions
Systematic reviews and evidence integration are becoming increasingly important in chemical risk assessments (Rooney et al., 2014; NRC, 2014; and Rhomberg et al., 2013) . Each phase of the systematic review and evidence integration process plays an important role in improving confidence and transparency in the risk assessment process. In conducting systematic reviews, the TCEQ:
Sets clear inclusion and exclusion criteria to promote transparency and limit subjective scientific judgment; Assesses data quality and conducts ROB analysis resulting in higher confidence in selection of the key studies and lessening uncertainty; and Weighs the evidence from different data streams prior to integrating the evidence, creating greater confidence in the final toxicity factor. This guidance document may be modified based upon experience with its implementation or as additional tools and resources become available.
Transparency document
Transparency document related to this article can be found online at https://doi.org/10.1016/j.yrtph.2017.10.008.
Appendix. Example of the Systematic review and evidence integration used in the Ethylene Glycol Development Support Document (DSD)
A.1 Problem formulation and protocol
Problem formulation identifies and describes the extent of the evaluation. These questions structured the systematic review for ethylene glycol (EG): Several studies were available, but some important studies were missing.
Two studies in different species, one 2-generation reproductive study, and two developmental studies were available. Systematic Review A systematic approach was not used. A systematic approach was considered and some criteria were applied, but a full review was not conducted.
A systematic approach was used in study evaluation and clear criteria were established for judgment. Key Study Quality Selected study has deficiencies, but is still considered useful.
Selected study was reasonably well done but limitations must be considered.
Selected study was well done and can be used without restriction.
Adverse effect Adverse effect or dose-response curve was moderate to severe. MOA information was not available.
Adverse effect was moderate; other studies are deemed necessary to determine the adverse effect.
Adverse effect was minimal severity, or the confidence in the adverse effect was high; MOA information was available. Relevance of Adverse Effect Adverse effect identified in animal studies is only assumed to be relevant to humans; MOA is not known for the adverse effect.
Adverse effect appears to be relevant to humans; MOA is assumed for the adverse effect and possibly relevant to humans Protocol development is another important aspect in the initial process. A protocol is typically developed around a PECO statement: Populations, Exposure, Comparator/Control, and Outcomes. These identifiers are used to lay out the framework for the literature search and inclusion/exclusion criteria. The PECO statement for EG followed the criteria in Table A As a first step, 2015 As a first step, publically available databases were searched using explicitly stated search criteria. Please see TCEQ (2015) for a list of available databases that were searched. The search terms used in the literature review for EG, along with the number of results from PubMed, are found in Table A .2. Additional references were also identified using the reference sections from some of the selected studies. This literature review was conducted in June 2015, and therefore studies published after this date were not available at the time of the review.
An additional PubMed search was conducted using the search terms "ethylene glycol" AND inhalation, which resulted in 105 references. These references were compared to the list generated above, and added as needed. The selected studies were imported into the Health Assessment Workspace Collaborative (HAWC) systematic literature review tool. As a team, each title and abstract was reviewed for relevance and tagged for either inclusion (human, animal, or mechanistic), or exclusion (not a relevant/applicable study). For EG, a number of studies involving cryopreservation and chemical synthesis were excluded due to the lack of relevance in a health-based risk assessment. Other reasons for initial exclusion included studies using chemicals other than EG (di-or triethylene glycol, ethylene glycol ethers, etc.), studies that did not look at toxic effects (bactericidal or solvent effects), and unrelated mechanistic studies.
Additionally, several governmental and private sector organizations were searched for published literature and toxicity values for EG, and the available documents are listed in Table A. 3. Relevant referenced articles from documents listed in Table A.3 were then added to the pool of selected material.
Following this initial review, which produced a pool of~170 articles and documents, specific inclusion and exclusion criteria were used to narrow down the pool of available data. The criteria, along with examples of the kinds of studies that were excluded, can be found in Table A .4. Using these inclusion/exclusion criteria, the pool of available data was narrowed down to 18 included studies: 7 human studies, 6 animal studies, and 5 mechanistic/in vitro studies. These studies were collected and reviewed in detail by each of the authors.
A.3 Data extraction
Each of the identified studies was reviewed in detail and the primary data was extracted for potential use in the Ethylene Glycol Development Support Document (DSD). Data from the studies can be found in Table A .5 (human studies), Table A.6 (animal studies), and Table A.7 (in vitro studies).
A.4 Study quality and risk of bias (ROB)
Each of the selected studies was evaluated for study quality and ROB based on a number of attributes determined prior to this review. The attributes were scored on a scale of 1 to À1, with 1 meaning the study possessed the specific attribute, 0 meaning the study did not examine the attribute, and À1 meaning the study lacked the attribute. Each of these study quality attributes along with the criteria used in scoring them can be found in Table A Rankings for each of the identified studies can be found in Table A .13 (human studies), Table A.14 (animal studies), and Table A .15 (in vitro studies) . Note that total scores were added as a guide to compare within the study groups; however, because each study group has a different number of scoring criteria, totals should not be compared across groups.
A.5 Evidence integration
After addressing the study quality and ROB for each of the selected studies, points were totaled to gain a better understanding of the quality of each paper and to compare the studies within each of the study groups. The information from each of the data streams (human, animal, and mechanistic) were then assessed for use as key, supporting, or informative studies based on the study quality criteria. As mentioned previously, because each study group has a different number of scoring criteria, totals were not compared across groups. The reasoning behind identifying each study as key, supporting or informative was compiled into the evidence integration tables found in Tables A16-A18. As seen in Table A .13 and A.16, Wills et al. (1974) was chosen as the key study for the derivation of the acute toxicity factors because a LOAEL of 140 mg/m 3 was identified for common complaints of respiratory irritation. As seen in Table A .14 and A.17, there were several animal studies of high quality; however, because human data are preferred when developing toxicity factors, the Wills et al. (1974) study was chosen as the key study. For derivation of the chronic toxicity factors, the Coon (1970) study was selected even though it did not score highest in the study quality scoring. Although overall both Tyl et al. (1995a &b) studies scored higher, these studies did not provide adequate POD values for use in toxicity factor development, and therefore were not selected as the key study. The human, animal and mechanistic studies that were not chosen as the key study were used either as supporting data or background information in the DSD.
A.6 Confidence Rating Table A .19 provides scoring criteria to rate the confidence and uncertainty for each aspect or element of the toxicity assessment. The table provides the name of the element and the magnitude of the confidence in each element using a qualitative ranking system of low, medium, or high confidence. Table A .20 displays the overall confidence in the ethylene glycol toxicity assessment. 
Population
General human population and any relevant sensitive subpopulations, animals (e.g., livestock), and vegetation Exposure Exposure to EG, surrogates with demonstrated with the same or similar MOAs, and any identified metabolites Comparator/Control Populations exposed to concentrations below the concentration that causes the most sensitive critical effect Outcome(s)
The most sensitive critical effect directly related to EG exposure Route of exposure is relevant to environmental exposure and to toxicity factor development -Exposure through i.v., i.p., or subcutaneous injection -Study examining dermal exposure -Study examining oral exposure* Relevant animal model and endpoints examined -Study used non-mammalian animal models -Endpoint studied not relevant to human health -Endpoint not applicable to toxicity factor development Human/Epi Route of exposure is relevant to toxicity factor development -Study examining dermal exposure -Study examining oral exposure* -Multiple routes possible/unknown route of exposure -Study focused on mortality/intentional ingestion Relevant endpoints examined i.v. e intravenous, i.p. e intraperitoneal. *Studies using the oral route of exposure were initially excluded from the key study selection due to the inhalation route being more applicable to the development of a ReV/ ESL. Oral data may be used to fill gaps in the inhalation data as needed. Neuronal degeneration, decrease in cell number Carney et al. (1996) Rat whole embryo culture 0. 5, 2.5, 12.5, 25, 50 mM EG or GA 48 h 50 mM EG, 2.5 mM GA 12.5 mM GA Inhibition of embryo growth and development Carney et al. (2008) Rabbit whole embryo culture 2. 5, 6, 12.5, 25, 50 Critical effect showed a significant negative dose-response curve Marshall and Cheng (1983) Rats Supporting -Health effects not directly measured, but also not reported -Free-standing NOAEL Tyl et al. (1995a) Rats and mice Informative -NOAEL and LOAEL for maternal and fetal toxicity -Two species tested -Significant oral exposure from grooming behaviors Tyl et al. (1995b) Mice Supporting -NOAEL and LOAEL for maternal and fetal toxicity -Minimum oral exposure due to nose-only exposure -Skeletal malformations linked to restraining apparatus Carney et al. (1996) Rat whole embryo culture Informative -Informative for MOA of EG and metabolites -Developmental study, fetal toxicity -Not clear if dose is relevant to human inhalation exposure Carney et al. (2008) Rabbit whole embryo culture Informative -Informative for MOA of EG and metabolites -Developmental study, fetal toxicity -Not clear if dose is relevant to human inhalation exposure Guo et al. (2007) Human proximal tubule cells Informative -Informative for MOA of EG and metabolites -Not clear if dose is relevant to human inhalation exposure Klug et al. (2001) Rat whole embryo culture Informative -Informative for MOA of EG and metabolites -Developmental study, fetal toxicity -Not clear if dose is relevant to human inhalation exposure Two studies in different species, one 2-generation reproductive study, two developmental studies Systematic Review A systematic approach was not used. A systematic approach was considered and some criteria were applied, but a full review was not conducted A systematic approach was used in study evaluation and clear criteria are established for judgment Key Study Quality Selected study has deficiencies, but is still considered useful Selected study was reasonably well done but some restrictions must be considered Selected study was well done and can be used without restriction Critical effect
Critical effect or dose-response curve was moderate to severe. MOA information not available.
Critical effect was moderate; other studies are deemed necessary to determine the critical effect.
Critical effect was of minimal, or the confidence in the critical effect was high. MOA information available.
Relevance of Critical Effect
Critical effect identified in animal studies is only assumed to be relevant to humans; MOA is not known for the critical effect
Critical effect appears to be relevant to humans. MOA is known for the critical effect and possibly relevant to humans.
Critical effect based on a human study or matches observed human experience; MOA is well understood so critical effect is assumed relevant. Beck et al. (2015) .
